Invention Grant
- Patent Title: Quinoline-substituted compound
-
Application No.: US15382883Application Date: 2016-12-19
-
Publication No.: US09758526B2Publication Date: 2017-09-12
- Inventor: Takao Uno , Katsumasa Nonoshita , Tadashi Shimamura
- Applicant: TAIHO PHARMACEUTICAL CO., LTD.
- Applicant Address: JP Tokyo
- Assignee: Taiho Pharmaceutical Co., Ltd.
- Current Assignee: Taiho Pharmaceutical Co., Ltd.
- Current Assignee Address: JP Tokyo
- Agency: Rothwell, Figg, Ernst & Manbeck, P.C.
- Priority: JP2013-172746 20130822
- Main IPC: C07D487/14
- IPC: C07D487/14 ; C07D471/14
Abstract:
An object to be achieved by the present invention is to provide a novel compound having EGFR inhibitory effects and cell growth inhibitory effects, as well as a medication useful for the prevention and/or treatment of cancer based on the EGFR inhibitory effects.The present invention provides a compound represented by Formula (I) below, or a salt thereof.
Public/Granted literature
- US20170101414A1 NOVEL QUINOLINE-SUBSTITUTED COMPOUND Public/Granted day:2017-04-13
Information query
